Medivation, Inc. (NASDAQ:MDVN)

CAPS Rating: 4 out of 5

A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.

Results 1 - 20 of 37 : 1 2 Next »

Recs

0
Member Avatar JohnBelg (61.37) Submitted: 4/29/2016 9:01:26 AM : Outperform Start Price: $56.17 MDVN Score: +3.09

Buyout bid by Sanofi.

Recs

0
Member Avatar manirg (< 20) Submitted: 8/7/2015 12:47:31 PM : Outperform Start Price: $49.38 MDVN Score: +18.08

undervalued , may get bought out soon

Recs

0
Member Avatar racoveanul (74.29) Submitted: 6/28/2015 5:26:20 AM : Outperform Start Price: $55.76 MDVN Score: +4.48

MEDIVATION INC, ticker MDVN, has a TTM ROE calculated by Zacks of 89,87%. It's one of my LONG picks.

Recs

0
Member Avatar WSMOOT19 (70.65) Submitted: 4/18/2015 12:44:19 AM : Outperform Start Price: $19.81 MDVN Score: +144.59

Good Value

Recs

1
Member Avatar biotechf (< 20) Submitted: 3/28/2015 5:17:55 PM : Outperform Start Price: $67.00 MDVN Score: -13.42

Strong revenue growth from Xtandi and recent label expansion mode well for this stock.

Recs

1
Member Avatar asilverp (66.56) Submitted: 8/26/2014 8:04:33 PM : Underperform Start Price: $44.30 MDVN Score: -27.53

At a stock price of 47 times book value, an unprofitable business and 162 dollars of debt for every dollar of equity what could possibly go wrong?

Recs

1
Member Avatar SkepBioInvestor (93.16) Submitted: 5/13/2014 5:00:37 PM : Outperform Start Price: $33.01 MDVN Score: +66.41

buyout candidate

Recs

2
Member Avatar baileysmom (< 20) Submitted: 1/26/2014 8:08:50 PM : Outperform Start Price: $38.83 MDVN Score: +33.64

Prostate cancer is not going away anytime soon and this drug is making a positive impact on patients. Easier to take 4 pills in the morning than sit in an infusion center for 3 hours. Also doesn't require Prednisone which is a plus over its rival J & J's Zytiga.

Recs

1
Member Avatar 1russianguy (46.23) Submitted: 10/9/2013 2:16:47 PM : Outperform Start Price: $25.25 MDVN Score: +104.46

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar 1picks (85.82) Submitted: 10/7/2013 11:15:22 AM : Outperform Start Price: $28.58 MDVN Score: +80.45

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

1
Member Avatar TMFEBCapital (44.23) Submitted: 9/20/2013 7:25:31 AM : Outperform Start Price: $30.05 MDVN Score: +72.62

MDVN's Xtandi has data coming for a pre-chemo prostate cancer indication and as a potential first line treatment for Xtandi too. Positive data from those trials would expand the patient pool and could significantly grow sales.

Recs

0
Member Avatar scotttu34 (< 20) Submitted: 6/17/2013 4:48:56 PM : Outperform Start Price: $23.79 MDVN Score: +117.55

Not much competition from other drug makers for their prostate cancer drug for probably a year or so.

Recs

0
Member Avatar genedom (97.29) Submitted: 2/3/2013 2:45:26 PM : Outperform Start Price: $28.33 MDVN Score: +66.80

Momentum

Recs

1
Member Avatar HIGHG33K (80.70) Submitted: 7/9/2012 3:33:54 PM : Outperform Start Price: $23.97 MDVN Score: +88.44

Will rule in prostate cancer field.

Recs

0
Member Avatar GoodTrader1 (< 20) Submitted: 6/6/2012 4:38:42 PM : Outperform Start Price: $21.97 MDVN Score: +108.53

high relative strenght

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:51:09 PM : Outperform Start Price: $18.22 MDVN Score: +167.20

went up 237% for portefeille.

Recs

1
Member Avatar lszachary (< 20) Submitted: 3/6/2012 9:26:53 PM : Outperform Start Price: $16.03 MDVN Score: +207.86

new prostate drug

Recs

0
Member Avatar HoldThatWinner (31.87) Submitted: 2/28/2012 9:05:53 PM : Underperform Start Price: $16.75 MDVN Score: -194.69

Another overinflated biotech that hasn't proven anything as of yet.

Recs

1
Member Avatar Olddognwtrx (< 20) Submitted: 11/20/2011 10:02:14 AM : Outperform Start Price: $10.37 MDVN Score: +385.59

MDV3100 looks as if it might take much of the prostate cancer market and work in breast cancer also. Sales of 2 billion on the low side. Someone will buy them after the launch. 100+ by the end of 2012. Buy on any dips and add slowly.

Recs

0
Member Avatar PharmaD (< 20) Submitted: 10/26/2011 11:11:58 PM : Outperform Start Price: $4.36 MDVN Score: +1,163.27

Phase 3 data coming soon..... And will likely be great

Results 1 - 20 of 37 : 1 2 Next »

Featured Broker Partners